Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
about
Reporting bias in medical research - a narrative reviewESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryBenefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adultsCardiovascular outcomes in trials of oral diabetes medications: a systematic reviewAn oxidized lipid-peroxisome proliferator-activated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesionNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesPPARs and the cardiovascular systemCardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical TrialsSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?PPAR-γ -- a possible drug target for complicated pregnanciesCrystallographic studies of human MitoNEETAssociation between extent of thiazolidinedione exposure and risk of acute myocardial infarctionRosiglitazone and myocardial infarction in patients previously prescribed metforminWhy we need easy access to all data from all clinical trials and how to accomplish itOphiocordyceps formosana improves hyperglycemia and depression-like behavior in an STZ-induced diabetic mouse modelThe current role of thiazolidinediones in diabetes management.Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.Anti-diabetic Agents in Type 2 Diabetes: A Review of New Data Presented and Discussed on the EASD meeting in Rome, 2008.Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.The risk of fractures associated with thiazolidinediones: a self-controlled case-series studyRosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.The metabolic syndromeRapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.Hypertension and diabetes: should we treat early surrogates? What are the cons?Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? YesTreatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records.Protective effect of the daming capsule on impaired baroreflexes in STZ-induced diabetic rats with hyperlipoidemia.AMPK activation: a therapeutic target for type 2 diabetes?Therapeutic interventions and oxidative stress in diabetesRandomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.Lack of association between adiponectin levels and atherosclerosis in mice.Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis.Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
P2860
Q21203744-7614D505-7D39-465D-BC7C-E73F8FCCDDEEQ22241786-DF8324EA-2A6D-46D0-908F-01A66670CB71Q22242077-0D33ECEB-49D1-411F-9F61-3E4A0EC07DBBQ22250879-8BC1879A-C114-4870-8581-9017B5DF29E4Q22253058-4C8A987D-8103-425B-B12A-CBF2242CD55CQ24300694-E63C76FD-C054-4884-9A21-96875C361D43Q24561401-C7F8B2FA-8CE8-4BA3-9C5B-6E2AD05555A0Q24642503-BF6E3406-4166-4EA3-8599-F0F673CE5869Q24642728-721AE9C0-3AB6-4080-AE00-5DB850FFB845Q26740247-F0BD2965-024B-4DBA-839D-CAA47375B114Q26748870-35F62C88-79BA-42E7-B7C9-FB08958C9060Q26750510-B0520A38-5974-42A5-82BB-1C923BAD0FAFQ26863678-EB156231-5632-468A-957B-E7B580FCEE3BQ27648680-B90BEF76-73D9-4149-959E-E034FE150DA7Q28396990-D73BC0C1-C528-46BA-B20E-1E58E1C1D48BQ28475672-30B04CC1-1ED6-4949-A2A8-4D6868187266Q28732492-3D113446-1EBA-4BCE-B868-7E85C01DD69BQ28829254-7E4A2B92-B26C-448D-94D4-CF0A42FE1D4BQ30250347-38BB5F3C-8A1E-4024-9826-076A6DBE94D6Q30384663-C1ADCA2F-E919-4261-907D-FD75749CC5CFQ30410721-FCC9F955-E5CC-48DD-AE8E-FF7AAFB36336Q33394779-BBFB7AC1-3D30-4D17-BBCE-5A830AC65FB3Q33398830-620EC17C-0E88-4334-BF13-24531EA1BB63Q33507247-FEC56E76-4253-41C9-ABE3-E22E0E1C9C35Q33556796-F3B08DFA-C1FF-44C8-90B4-107F3BA2A69EQ33561396-E9B476D5-F5AB-42BC-8463-FC1DC6552C2AQ33569142-369F6173-60AB-4E1B-8F2F-79360EE75900Q33575808-B9A826C1-E7F4-4BBD-8189-559FF0B3498CQ33610656-3DE7E3A9-CA43-4874-A579-72CC6877DD8BQ33610682-63C3A859-9900-4C06-847E-04AA967ACDBDQ33654306-0224C733-D34F-46F1-8B8D-A2FAAC77D1AFQ33683650-5F38AB84-FF0E-41F8-B38D-5893673D0303Q33777472-AD6BFCC6-114C-4B1B-840C-90AE7102C730Q33824564-747D467A-7E9A-405D-A08B-77E86F00A0F0Q33870395-722286B2-413D-4402-AB7F-14A4EA48EBFEQ33932712-1EC8E2F6-DF43-4E6C-B333-E585DE71BD8EQ33958420-D6E90FBB-EACE-44E8-A5B5-288399D855E0Q34016939-45FDA31E-2E04-40D8-AB47-6B271BFD5695Q34023636-F3B218B2-57C0-487C-99A2-0CAA207F99BEQ34056132-8DC0DD32-5704-47B5-B804-107819A85D6C
P2860
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@ast
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@en
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@nl
type
label
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@ast
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@en
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@nl
prefLabel
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@ast
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@en
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@nl
P2093
P50
P356
P1476
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
@en
P2093
Henning Beck-Nielsen
John J V McMurray
Nigel P Jones
Philip D Home
RECORD Study Group
Ramón Gomis
Stuart J Pocock
P356
10.1056/NEJMOA073394
P407
P577
2007-06-05T00:00:00Z